FIELD: medicine.
SUBSTANCE: group of inventions relates to the field of medicine and is intended for the treatment of human diseases caused by gram-positive bacteria. As an antibacterial agent, eremomycin is used, or its pharmaceutically acceptable salts and solvates. Dose is 20 to 2,000 mg per day, while the administered eremomycin contains, as an impurity, dezaremozaminil-eremomycin not more than 3 % by weight.
EFFECT: group of inventions allows expanding the arsenal of therapeutic agents.
25 cl, 11 ex, 9 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| NEW SEMI-SYNTHETIC EREMOMYCINE DERIVATIVE AND ITS APPLICATION | 2016 |
|
RU2641912C1 |
| COMPOUNDS FOR TREATING CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASES | 2011 |
|
RU2575477C2 |
| N-(GUANIDINOALKYL) AMIDES OF EREMOMYCIN AND THEIR USE FOR TREATING BACTERIAL INFECTIONS | 2022 |
|
RU2815029C1 |
| ANTIBACTERIAL COMPOUNDS | 2009 |
|
RU2525915C2 |
| 5-HYDROXYMETHYLOXAZOLIN-2-ONE DERIVATIVES FOR TREATING BACTERIAL INTESTINAL DISEASES | 2009 |
|
RU2527769C2 |
| NEW DERIVATIVES OF EREMOMYCIN AMIDE AND APPLICATION THEREOF FOR TREATING BACTERIAL INFECTIONS | 2020 |
|
RU2751334C1 |
| METHODS FOR TREATMENT AND PREVENTION OF C. DIFFICILE INFECTION | 2017 |
|
RU2751509C1 |
| HYBRID ANTIBACTERIAL AGENTS OXAZOLIDINONE-QUINOLONE INTENDED FOR PARENTERAL ADMINISTRATION FOR TREATMENT OR PREVENTION OF BACTERIAL DISEASES | 2014 |
|
RU2702364C2 |
| NOVEL DERIVATIVES OF EREMOMYCIN AND USE THEREOF FOR TREATING BACTERIAL INFECTIONS | 2019 |
|
RU2708628C1 |
| NOVEL ANTIBACTERIAL MEDICATIONS FOR TREATMENT OF GRAM-POSITIVE INFECTIONS | 2009 |
|
RU2512396C2 |
